Latest action: Received in the Senate and Read twice and referred to the Committee on Commerce, Science, and Transportation.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Establishes safety standards for nucleic acid materials to prevent biosecurity threats.
The problem
Nucleic acids can be misused to create dangerous biological threats. The U.S. needs clear standards to keep these materials safe and secure.
The proposal
Creates requirements for how nucleic acid materials are tested, labeled, and handled. Sets biosecurity standards that companies and researchers must follow.
The impact
Affects laboratories, biotech companies, researchers, and suppliers of nucleic acids. Increases compliance requirements and safety oversight across the industry.
Clear standards help prevent dangerous materials from being misused to create biological weapons. This protects public health and national security by controlling access to risky materials.
Establishes clear rules so legitimate scientists know exactly what they must do. Makes it easier for good research to continue while bad actors are stopped.
U.S. leadership on biosecurity standards helps American companies compete globally. Countries that adopt these standards may prefer doing business with U.S. firms.
Removes confusion by creating one set of rules instead of many different rules. Everyone follows the same standards, making enforcement easier and fairer.
Small labs and companies may struggle to afford new equipment and testing required by standards. Larger companies have more resources, which could hurt smaller competitors.
New safety requirements and paperwork could delay legitimate scientific research and medical breakthroughs. Extra steps in the process take time and money.
New government oversight means more inspections, reporting, and documentation for companies. This creates administrative work and costs that may not improve safety much.
Strict rules might discourage new companies from entering the biotechnology field. Startups especially could find it hard to meet expensive new requirements.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Other bills in this policy area
HR 10671
Securing Our Critical Infrastructure Act
HR 10695
United States Submarine Cable Security Policy Act of 2026
HR 7022
Mystic Alerts Act
S 5668
Methane Monitoring Science Act of 2026
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.